A number of clinical trials with anti-inflammatory drugs, such as a monoclonal antibody against TNFα and an interleukin-1 receptor antagonist have been conducted to counteract the pathological inflammatory response in bacterial sepsis with little to no success43,44. Here, TNF is linked to bacterial infectious disease with sepsis.